1. In patients with previously treated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), treatment with sacituzumab ...
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with rheumatoid arthritis (RA) was associated with ...
1. Management of pediatric ulcerative colitis with tofacitinib successfully induced corticosteroid-free remission in 16% of patients at week 8 following ...
1. Dupilumab treatment for bullous pemphigoids resulted in improved clinical symptoms. 2. Patients with anti-BP180 antibody levels of at least ...
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
1. Treatment with biologics in pediatric patients with moderate to severe psoriasis was significantly associated with greater reduction in psoriasis ...
